NASDAQ · AVIR
Healthcare · Biotechnology
$5.01
Down-$0.06 (-1.18%)
Updated Oct 8, 2026, 2:15 AM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · AVIR
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
AVIR closed at $5.01 after 21 trading sessions, down 4.93% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $5.02 | $5.23 | $4.99 | $5.01 | 264.77K |
| Oct 6, 2026 | $5.16 | $5.19 | $4.98 | $5.07 | 229.37K |
| Oct 5, 2026 | $5.12 | $5.18 | $4.945 | $5.13 | 293.61K |
| Oct 2, 2026 | $5.16 | $5.215 | $5.05 | $5.13 | 253.26K |
| Oct 1, 2026 | $5.16 | $5.20 | $4.93 | $5.10 | 408.66K |
| Sep 30, 2026 | $5.20 | $5.29 | $5.14 | $5.21 | 296.28K |
| Sep 29, 2026 | $5.20 | $5.23 | $5.08 | $5.18 | 298.35K |
| Sep 28, 2026 | $5.15 | $5.30 | $5.10 | $5.20 | 238.37K |
| Sep 25, 2026 | $5.16 | $5.21 | $5.04 | $5.17 | 280.67K |
| Sep 24, 2026 | $5.28 | $5.305 | $5.14 | $5.17 | 228.81K |
| Sep 23, 2026 | $5.60 | $5.60 | $5.25 | $5.28 | 232.34K |
| Sep 22, 2026 | $5.46 | $5.655 | $5.38 | $5.64 | 237.55K |
| Sep 21, 2026 | $5.36 | $5.52 | $5.325 | $5.43 | 440.1K |
| Sep 18, 2026 | $5.21 | $5.37 | $5.17 | $5.33 | 600.44K |
| Sep 17, 2026 | $5.21 | $5.33 | $5.20 | $5.26 | 279.43K |
| Sep 16, 2026 | $5.23 | $5.33 | $5.15 | $5.15 | 274.18K |
| Sep 15, 2026 | $5.30 | $5.30 | $5.12 | $5.23 | 224.33K |
| Sep 14, 2026 | $5.31 | $5.455 | $5.25 | $5.32 | 272.76K |
| Sep 11, 2026 | $5.23 | $5.41 | $5.18 | $5.31 | 489.58K |
| Sep 10, 2026 | $5.22 | $5.30 | $5.17 | $5.18 | 251.13K |
| Sep 9, 2026 | $5.64 | $5.66 | $5.24 | $5.27 | 430.82K |
The latest Smart Investors Daily articles mentioning AVIR.
Company
Market Activity
Research & News
AVIR research
Company profile and research snapshot.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2026 | Morgan Stanley | Equal-Weight | — |
| Mar 9, 2026 | Evercore ISI Group | Outperform | — |
| Apr 11, 2025 | Morgan Stanley | Equal-Weight | — |
| Aug 13, 2024 | Morgan Stanley | Equal-Weight | — |
| Aug 10, 2023 | JP Morgan | Underweight | — |
No generated briefing is available yet.
SeekingAlpha · Sep 15, 2026
Atea Pharmaceuticals, Inc. (AVIR) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 12:20 PM EDTCompany ParticipantsJean-Pierre...
Yahoo · Sep 8, 2026
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, together with other members of the Atea management team, will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, Septembe
Yahoo · Aug 19, 2026
HCV regimen met non-inferiority with 8-week dosing for non-cirrhotic patients.
Benzinga · Aug 13, 2026
Morgan Stanley analyst Matthew Harrison maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Equal-Weight and raises the price target from $6 to $7.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AVIR.
